产品
编 号：F231521
分子式：C28H32FN3O5
分子量：509.57
分子式：C28H32FN3O5
分子量：509.57
产品类型
规格
价格
是否有货
结构图
CAS No: 1854901-94-2
产品详情
生物活性：
TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).
体内研究：
TAK-828F (0.3, 1, and 3 mg/kg; orally administered; b.i.d.; 28 days; in mice with IL-23-induced cytokine expression model) shows robust and dose-dependent inhibition of IL-17A expression with an ED80 of 0.5 mg/kg.Animal Model:Mice with IL-23-induced cytokine expression model
Dosage:0.3, 1, and 3 mg/kg
Administration:Orally administered; b.i.d.; 28 days
Result:Showed robust and dose-dependent inhibition of IL-17A expression (ED80=0.5 mg/kg).
TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).
体内研究：
TAK-828F (0.3, 1, and 3 mg/kg; orally administered; b.i.d.; 28 days; in mice with IL-23-induced cytokine expression model) shows robust and dose-dependent inhibition of IL-17A expression with an ED80 of 0.5 mg/kg.Animal Model:Mice with IL-23-induced cytokine expression model
Dosage:0.3, 1, and 3 mg/kg
Administration:Orally administered; b.i.d.; 28 days
Result:Showed robust and dose-dependent inhibition of IL-17A expression (ED80=0.5 mg/kg).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备